pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Parabilis Medicines · news · pharmadog
← back to Parabilis Medicines
News mentioning Parabilis Medicines
49
stories
7d
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
biospace
21d
Once undruggable, the Wnt/B-catenin pathway shows increasing promise
biospace
25d
Biotech IPOs raise $7.5B as sector’s performance rally flattens
biospace
28d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
29d
Biotech notches 31 IPOs already this year, with 4 more joining queue
biospace
Oct 16, 26
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
biospace
Oct 15, 26
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
Oct 11, 26
The 2026 Biotech Graveyard
fiercebiotech
Oct 10, 26
Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
fiercebiotech
Oct 9, 26
Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
fiercebiotech
Oct 8, 26
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 6, 26
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
Sep 25, 26
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
Sep 22, 26
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 21, 26
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
Sep 18, 26
Inflammation biotech Electra charges up with $350M from upsized IPO
fiercebiotech
Sep 14, 26
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
Sep 8, 26
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
Sep 6, 26
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Aug 26, 26
JATT mastermind launches latest biotech-focused SPAC via $60M IPO
fiercebiotech
Aug 25, 26
Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
biospace
Aug 25, 26
Young startups miss out on biotech venture funding rebound, MassBio says
biopharma dive
Aug 20, 26
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
Aug 7, 26
2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
biospace
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 6, 26
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
← prev
page 1 of 2
next →